Spondyloarthritis & psoriatic arthritis
Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study
An erratum to this article was published (RMD Open, 12 Aug 2025 ↗)
Authors' conclusion
Retention rates were somewhat lower for axSpA than for PsA. For both axSpA and PsA, prior IL-17i treatment was associated with an increased risk of withdrawal
Study context
- Population
- Danish patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) initiating ixekizumab (IL-17i) between 2017 and 2024, DANBIO registry; most bio-experienced (axSpA 97%, PsA 91%)
- Participants
- 709 patients
- Exposure
- axSpA vs PsA
- axSpAn = 231
- PsAn = 478
- Outcome
- 6-, 12- and 24-month retention rates and low disease activity (LDA)/remission after 6 months (axSpA: Axial Spondyloarthritis Disease Activity Score (ASDAS) <2.1/<1.3; PsA: DAPSA28 ≤14/≤4)
- Follow-up
- 6, 12 and 24 months
Methodological detailsnationwide, registry-based (DANBIO), multivariable Cox regression
- Nationwide
- Registry-based (DANBIO)
- Multivariable Cox regression
Main finding
As reported in the abstract
Ixekizumab retention rate
| Group | Value | 6-month retention | 12-month retention | 24-month retention |
|---|---|---|---|---|
| axSpA | 69% (95% CI 63–76) | 69% (95% CI 63; 76) | 53% (46; 60) | 40% (33; 49) |
| PsA | 75% (95% CI 71–79) | 75% (71; 79) | 63% (58; 67) | 51% (46; 57) |
Value
axSpA69% (95% CI 63–76)
PsA75% (95% CI 71–79)
6-month retention
axSpA69% (95% CI 63; 76)
PsA75% (71; 79)
12-month retention
axSpA53% (46; 60)
PsA63% (58; 67)
24-month retention
axSpA40% (33; 49)
PsA51% (46; 57)
Observational data: associations, not effects.
Further findings
Withdrawal with prior treatment with another IL-17i (axSpA 36%, PsA 34%)
| aHR (CI) | ||
|---|---|---|
| axSpAPrior IL-17ivs none | 1.48 (1.01–2.17) | |
| PsAPrior IL-17ivs none | 2.38 (1.79–3.15) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
| Outcome | axSpA | PsA |
|---|---|---|
| LDA and remission · 6 monthsValue shown is LDA | ||
| ASDAS-LDA | 24% | — not stated in the abstract |
| ASDAS-remission | 5% | — not stated in the abstract |
| DAPSA28-LDA | — not stated in the abstract | 43% |
| DAPSA28-remission | — not stated in the abstract | 10% |
— not stated in the abstract
Other factors and withdrawal
- Smoking, radiographic status (axSpA) or concomitant MTX (PsA) not associated with withdrawal
Original publication
Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study. RMD Open. Published 22 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →